Already a member? Sign in
Entacapone is an inhibitor of catechol-O-methyltransferase (COMT) and is indicated as an adjunct treatment for patients taking levodopa and carbidopa for Parkinson’s Disease who experience the signs and symptoms of end-of-dose “wearing-off”.
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| Parkinson's Disease | 187 | 26 |
|
|
|
|
|
| Increase effect of another treatment | 39 | 9 |
|
|
|
|
|
| Wearing off effect | 15 | 5 |
|
|
|||
| Other | 7 | 3 |
|
|
|||
| Stiffness/Spasticity | 6 | 1 |
|
||||
| to extend effect of Sinimet | 5 | 2 |
|
|
See all 228 patients currently taking Entacapone
Mouse over the table for more information
Commonly reported side effects, conditions, and hospitalizations associated with Entacapone
| Digestive problems | 5 | |
|---|---|---|
| Dyskinesia | 5 | |
| Constipation | 4 | |
| Nausea | 3 | |
| on-off time | 2 | |
| Excessive perspiration (hyperhidrosis) | 2 | |
| See all 21 reported side effects ▼ | ||
Frequently reported dosages based on patients currently taking Entacapone. See all 18 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Did not seem to work | 20 | ||
| Side effects too severe | 20 | ||
| Doctor's advice | 17 | ||
| Other | 11 | ||
| Expense | 6 | ||
| Personal research | 1 | ||
| Not indicated | 1 | ||
| Course of treatment ended | 1 |
Adherence
Taking treatment as prescribed
Adherence of Entacapone
Always |
35 | 74% |
|
|---|---|---|---|
Usually |
12 | 26% |
|
Sometimes |
0 | 0% |
|
Never |
0 | 0% |
|
Burden
Difficulty being on treatment
Burden of Entacapone
Very |
3 | 6% |
|
|---|---|---|---|
Somewhat |
8 | 17% |
|
A little |
7 | 15% |
|
Not at all |
29 | 62% |
|
Cost
Paid out of pocket
Cost of Entacapone
$200+ |
4 | 12% |
|
|---|---|---|---|
$100-199 |
3 | 9% |
|
$50-99 |
1 | 3% |
|
$25-49 |
11 | 32% |
|
< $25 |
15 | 44% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on February 10, 2012.